XM does not provide services to residents of the United States of America.

Goldman Sachs cuts STOXX 600 forecast for next 12 months



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Goldman Sachs cuts STOXX 600 forecast for next 12 months</title></head><body>

Updates throughout

By Gokul Pisharody

Nov 19 (Reuters) -Goldman Sachs cut its forecast for Europe's benchmark equity index STOXX 600 .STOXX for the next 12 months, citing the persistently weak economic performance of the region and dull corporate earnings growth.

"Europe's problems are well recognized – low economic growth, high political uncertainty and a lack of decisive policy response" and would continue to weigh on the region's performance, Goldman Sachs analysts said in a note on Tuesday.

The brokerage, however, still sees "positive but low returns" for STOXX 600, and cut its forecast to 530 from 540 points. The benchmark European index last closed at 502.61 points.

The index has risen about 4.8% this year, compared with a 23.08% jump in its U.S. counterpart, the S&P 500 index .SPX.

Shortly before his U.S. presidential election victory, Trump had warned that the 27-nation bloc would have to "pay a big price" for not buying enough American exports, and EU officials say that his threats of 10% tariffs on all imports and 60% on those from China are credible and not just campaign rhetoric.

Goldman, however, sees a negligible impact on the index from Trump's tariffs as it expects the tariffs to be selectively applied.

It believes that a resolution to the war in Ukraine and a decisive policy from Europe are some key factors that could boost the index, but it remains skeptical of any near-term relief.

"But one area we do see support from is continued disinflation in Europe," Goldman added.

The brokerage also cut its forecast for UK's benchmark FTSE 100 index .FTSE for the next 12 months to 8,500 from 8,800 points.



Reporting by Gokul Pisharody in Bengaluru; Editing by Mrigank Dhaniwala and Shinjini Ganguli

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.